Diagnosis Sheet
Trauma- and Stressor-Related Disorders DSM-5-TR 309.81 | ICD-10-CM F43.10
Posttraumatic Stress Disorder
Persistent intrusion, avoidance, negative alterations in cognition and mood, and hyperarousal lasting beyond one month after trauma.
Lifetime prevalence~6.8% (US adults)
Typical onsetWithin 3 months of trauma
Sex ratio~2:1 female:male
Course~50% remit within 1 year
Clinical picture
- Intrusions are involuntary and sensory rather than deliberate recall: flashbacks, nightmares, and cue-triggered distress with autonomic surge.
- Avoidance of reminders progressively narrows life domains, and patients present for insomnia, pain, or substance use rather than for trauma.
- Negative cognitions center on self-blame, permanent damage, and a foreshortened future, accompanied by persistent shame, guilt, and anger.
- Hyperarousal includes hypervigilance, exaggerated startle, irritability or aggression, reckless behavior, and fragmented sleep.
- Depersonalization or derealization mark a dissociative subtype associated with early, repeated interpersonal trauma and worse function.
- Children may show trauma reenactment in play, frightening dreams without recognizable content, and developmental regression rather than verbal report.
Criteria snapshot
- Requires exposure to actual or threatened death, serious injury, or sexual violence, directly, as a witness, by learning of it, or through repeated occupational exposure.
- Symptoms span four clusters: at least one intrusion, one avoidance, two negative alterations in cognition and mood, and two arousal or reactivity symptoms.
- Duration must exceed one month with clinically significant distress or impairment, and symptoms cannot be attributable to substances or medical illness.
- Specify with dissociative symptoms, or with delayed expression when full criteria are not met until at least six months after the event.
- A separate developmental criteria set applies to children age six and younger, requiring fewer symptoms and using behavioral anchors.
Neurobiology
- Amygdala hyperreactivity with reduced ventromedial prefrontal inhibition impairs fear extinction learning and, critically, extinction recall.
- Hippocampal volume reduction correlates with symptom severity and degrades contextual discrimination between genuinely safe and dangerous cues.
- The HPA axis shows low cortisol with enhanced glucocorticoid receptor sensitivity and exaggerated negative feedback, opposite the pattern in depression.
- Noradrenergic hyperactivity originating in the locus coeruleus underlies startle and nightmares and provides the rationale for prazosin.
- Twin heritability is roughly 30-40%, and FKBP5 variants interact with childhood adversity to raise risk after adult trauma exposure.
- Chronic PTSD carries elevated rates of cardiovascular disease, metabolic syndrome, autoimmune illness, and later dementia.
Psychology
- Two-factor learning theory: fear is classically conditioned to trauma cues, then avoidance is negatively reinforced and blocks natural extinction.
- Emotional processing theory holds that a fragmented fear structure must be activated and then met with corrective information to change.
- The cognitive model emphasizes stuck points, distorted appraisals of ongoing danger, self-blame, and beliefs assimilated to preserve prior worldview.
- Peritraumatic dissociation, prior trauma, low social support, and poor post-trauma support predict chronicity more strongly than event severity.
- Moral injury, institutional or caregiver betrayal, and guilt often respond better to cognitive approaches than to exposure-only protocols.
Differential & comorbidity
- Acute stress disorder covers 3 days to 1 month; adjustment disorder covers non-Criterion A stressors or subthreshold responses to trauma.
- Differentiate from panic disorder, OCD intrusions, traumatic brain injury sequelae, and psychotic disorders with true hallucinations.
- Comorbidity is the rule: major depression in about half of patients, alcohol or substance use disorders in 30-50%, and frequent chronic pain.
- Suicide risk is elevated roughly two- to threefold, so assess ideation, means access, and reckless behavior at every clinical contact.
- Screen veterans for TBI, obstructive sleep apnea, and hearing loss, since untreated sleep pathology blunts response to trauma therapy.
Pharmacologic treatment
- Sertraline 50-200 mg/day and paroxetine 20-60 mg/day are FDA-approved, and venlafaxine XR 75-225 mg/day has comparable evidence.
- Allow 8-12 weeks at an adequate dose; effect sizes are modest and VA/DoD guidance prefers trauma-focused psychotherapy first-line.
- Prazosin 1-15 mg at bedtime reduces trauma-related nightmares in many patients; titrate slowly and monitor orthostatic hypotension.
- Avoid benzodiazepines, which impair extinction learning, worsen long-term outcomes, and carry high dependence risk in this population.
- Do not use antipsychotics routinely; adjunctive risperidone showed no benefit over placebo in the large VA cooperative study.
Psychotherapy
- Trauma-focused therapies are first-line: prolonged exposure, cognitive processing therapy, and EMDR, each across 8-16 sessions.
- Cognitive processing therapy addresses stuck points over 12 sessions and can be delivered with or without a written trauma account.
- Prolonged exposure combines in vivo and imaginal exposure with post-exposure processing across 8-15 sessions of 60-90 minutes.
- Written exposure therapy achieves noninferior outcomes in only five sessions and produces markedly lower dropout rates.
- Trauma-focused CBT is the standard for children and adolescents, running 12-16 sessions with structured caregiver participation.
Adjunct options
- Administer the PCL-5 at baseline and every 2-4 weeks; a 10-20 point decrease indicates clinically meaningful improvement.
- Treat sleep directly with CBT-I and imagery rehearsal therapy, since residual insomnia and nightmares predict relapse.
- Concurrent treatment of substance use disorder alongside trauma-focused therapy outperforms requiring abstinence before starting.
- Aerobic exercise, trauma-sensitive yoga, and mindfulness lower hyperarousal but do not substitute for trauma-focused psychotherapy.
- MDMA-assisted therapy is not FDA-approved; the 2024 application drew a complete response letter and further trials are ongoing.
Clinical pearls
- Benzodiazepines block extinction learning; they make PTSD worse, not better.
- Prazosin at bedtime for nightmares; titrate slowly and check orthostatic vitals.
- Trauma-focused psychotherapy beats medication; lead with PE, CPT, or EMDR.
References
- American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
- American Psychological Association. (2017). Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults. https://www.apa.org/ptsd-guideline
- National Institute for Health and Care Excellence. (2018). Post-traumatic stress disorder (NICE guideline NG116). https://www.nice.org.uk/guidance/ng116
- National Institute of Mental Health. (n.d.). Post-traumatic stress disorder. U.S. Department of Health and Human Services. https://www.nimh.nih.gov/health/topics/post-traumatic-stress-disorder-ptsd
- Sadock, B. J., Sadock, V. A., & Ruiz, P. (2021). Kaplan & Sadock's synopsis of psychiatry (12th ed.). Wolters Kluwer.
- Stahl, S. M. (2021). Stahl's essential psychopharmacology (5th ed.). Cambridge University Press.
- U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder (Version 4.0). https://www.healthquality.va.gov/guidelines/MH/ptsd/